Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia - Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York)) ; DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ; Chromik, Jörg (Goethe University Frankfurt) ; Chatterjee, Manik (University Hospital of Würzburg) ; Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ; Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ; Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ; de Vos, Filip (University Medical Center Utrecht) ; Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Cassier, Philippe A. (Léon Bérard Center) ; Tai, David (National Cancer Center Singapore) ; Kiladjian, Jean-Jacques (Université de Paris) ; Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ; Mous, Rogier (University Medical Center Utrecht) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ; Ferretti, Stephane (Novartis Institutes for Biomedical Research) ; Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ; Meille, Christophe (Novartis Institutes for Biomedical Research) ; Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ; Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ; Mariconti, Luisa (Novartis Institutes for Biomedical Research) ; Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ; Fabre, Claire (Novartis Institutes for Biomedical Research) ; Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona